Novel Targets in the Ovarian Cancer Treatment Paradigm

Investigators are hoping to dramatically improve the platinum-resistant ovarian cancer treatment paradigm with the development of the first-in-class antibody-drug conjugate upifitamab rilsodotin.

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.

Debra L. Richardson, MD, FACS, FACOG, discusses the role of NaPi2b as a target for upifitamab rilsodotin, data that have emerged from the ongoing phase 1/2 UPLIFT trial, and the development of other studies like UPNEXT and UPGRADE that are further evaluating upifitamab rilsodotin in patients with ovarian cancer.

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the unmet needs for patients with ovarian cancer and the clinical trials that seeking to address those needs, including the ADC upifitamab rilsodotin.

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.